[Federal Register Volume 85, Number 129 (Monday, July 6, 2020)]
[Notices]
[Pages 40290-40291]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14417]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2020-0051]


Request for Information Concerning Personnel and the Retention of 
Next Generation Sequencing Data in Clinical and Public Health 
Laboratories; Extension of Comment Period

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: On May 15, 2020, the Centers for Disease Control and 
Prevention (CDC), located within the Department of Health and Human 
Services (HHS) published a notice in the Federal Register requesting 
public comment on the Request for Information Concerning Personnel and 
the Retention of Next Generation Sequencing Data in Clinical and Public 
Health Laboratories (85 FR 29456). Written and electronic comments were 
to be received on or before July 14, 2020. HHS/CDC has received a 
request asking for a 60-day extension of the comment period. In 
consideration of this request, HHS/CDC is extending the comment period 
to September 14, 2020.

DATES: Written comments must be received on or before September 14, 
2020.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2020-
0051 by any of the following methods only. CDC does not accept comment 
by email.
    Internet: Access the Federal eRulemaking portal at http://www.regulations.gov. Follow the instructions for submitting comments.
    Mail: Heather Stang, MS, MT, Division of Laboratory Systems, 
Centers for Disease Control and Prevention, 1600 Clifton Road NE, 
Mailstop V24-3, Atlanta, GA 30329. Docket No. CDC-2020-0051.
    All relevant comments received will be posted publicly without 
change, including any personal or proprietary information provided. To 
download an electronic version of the plan, please access http://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: Heather Stang, MS, MT, Center for 
Surveillance, Epidemiology and Laboratory Services, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, 
GA 30329, telephone (800) 232-4636; email: [email protected].

[[Page 40291]]


SUPPLEMENTARY INFORMATION:

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data about topics 
related to personnel performing informatics activities, as well as data 
storage and retention practices related to the use of next generation 
sequencing (NGS) technology. In addition, CDC invites comments 
specifically on the following questions:
    (1) What are the roles and responsibilities for all personnel 
performing bioinformatics or pathology/laboratory informatics 
activities? What training is considered essential for each of the 
roles? What competencies are considered essential for each of the 
roles? What minimum educational requirements (degrees or courses) are 
required for each of the roles?
    (2) What are the challenges for recruitment and retention of 
bioinformatics or pathology/laboratory informatics personnel?
    (3) What are examples of how NGS data files are used in addition to 
generating a clinical test result?
    (4) What NGS data files should be retained for quality assurance, 
repeat analyses, or subsequent analyses? How long should these NGS data 
files be retained?
    (5) What are the challenges and approaches for laboratories to 
maintain and utilize previous versions of sequence analysis software?
    Please note that comments received, including attachments and other 
supporting materials, are part of the public record and are subject to 
public disclosure.
    Comments will be posted on https://www.regulations.gov. Therefore, 
do not include any information in your comment or supporting materials 
that you consider confidential or inappropriate for public disclosure. 
If you include your name, contact information, or other information 
that
    identifies you in the body of your comments, that information will 
be on public display. Do not submit public comments by email. CDC will 
review all submissions and may choose to redact, or withhold, 
submissions containing private or proprietary information such as 
Social Security numbers, medical information, inappropriate language, 
or duplicate/near duplicate examples of a mass-mail campaign.

Background and Brief Description

    Clinical laboratory testing technology has advanced significantly 
since the CLIA regulations were first implemented approximately 30 
years ago. Next generation sequencing (NGS) technologies provide the 
high-throughput capability to rapidly and cost-effectively sequence 
large regions and mixed populations of DNA and RNA, when compared to 
traditional sequencing methods. This technology results in a 
significant increase in data that requires specialized analysis to 
derive a clinically meaningful result. NGS has led to improvements in 
diagnoses and patient care in many areas of medicine that include 
medical genetics, pediatrics, oncology, and microbiology. In some 
instances, NGS has led to life-saving diagnoses and treatment pathways, 
not achievable using other testing modalities. One element that 
differentiates NGS from most laboratory methodologies is its 
significant reliance on informatics to achieve a meaningful and 
reportable result. As a consequence, clinical laboratories require 
personnel knowledgeable in bioinformatics or pathology/laboratory 
informatics to design and manage the bioinformatics analysis.
    While CLIA regulations apply to clinical NGS testing, there is a 
lack of clarity regarding how the general CLIA quality system and 
personnel requirements should be specifically implemented for the NGS 
bioinformatics components. In April 2019, CLIAC made eight 
recommendations regarding CLIA's application to NGS-based technologies. 
This request for information is soliciting comments from the public for 
more information on topic areas mentioned in two of the 
recommendations, specifically, the qualifications of personnel 
performing bioinformatics activities; storage and retention of NGS data 
files; and maintenance of sequence analysis software. The April 2019 
CLIAC summary is available in the docket under the Supporting Materials 
tab and at https://www.cdc.gov/cliac/past-meetings.html.
    The qualifications and responsibilities of personnel performing the 
informatics component of the testing process are not addressed in the 
CLIA regulations. For the purpose of this request for information, the 
informatics component of NGS includes the analysis of NGS machine-
generated data and subsequent computational processes. Therefore, CDC 
is asking the public to describe different responsibilities of 
personnel providing bioinformatics or pathology/laboratory informatics 
expertise such as validating and assuring that the informatics pipeline 
meets documented performance specifications.
    CDC is also interested in learning the skills, training, and 
education of personnel who will fill bioinformatics or pathology/
laboratory informatics positions, and how clinical and public health 
laboratories can recruit and retain personnel with these identified 
skills.
    Lastly, the NGS testing process generates large amounts of data and 
requires multiple file types. CLIA regulations specify at 42 CFR 
493.1105(a)(3) that all
    analytic systems records must be kept for at least two years, but 
the regulations do not specify the types of data to be captured or the 
retention time for a given data type. The regulations do not address 
the capability to access and reanalyze the data after the test is 
performed. This capability may require retention of the version of 
software used in the original analysis. CDC requests comment from the 
public on this topic.
    HHS/CDC has posted all related materials to the docket on 
www.regulations.gov.

    Dated: June 30, 2020.
Sandra Cashman,
Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2020-14417 Filed 7-2-20; 8:45 am]
BILLING CODE 4163-18-P